To identify protein markers associated with a positive response to gonadotropin treatment, a proteomic approach to analyze the secretome of KGN cells, a human granulosa-like tumor cell line, following FSH, hCG, and a combined FSH/hCG stimulation was used. Here, BRD2 is linked to neoplasm.